Cargando…

Modeling the Ex Ante Clinical Real Option Value in an Innovative Therapeutic Area: ALK-Positive Non-Small-Cell Lung Cancer

OBJECTIVES: A drug that improves survival and/or disease progression can create real option value (ROV)—the additional health gain from future innovations enabled by a longer survival. ROV can be a relevant consideration for both clinical and payer decision-makers. We aimed to estimate the ex ante R...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, Woojung, Wong, William B., Kowal, Stacey, Garrison, Louis P., Veenstra, David L., Li, Meng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2022
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9130184/ https://www.ncbi.nlm.nih.gov/pubmed/35527331 http://dx.doi.org/10.1007/s40273-022-01147-5

Ejemplares similares

Real-world evidence for option value in metastatic melanoma
por: Wong, William B, et al.
Publicado: (2021)

Ex‐ante evaluation of promising soybean innovations for sub‐Saharan Africa
por: Gbegbelegbe, Sika, et al.
Publicado: (2019)

ALK Inhibitors or Chemotherapy for Third Line in ALK-positive NSCLC? Real-world Data
por: Moskovitz, Mor, et al.
Publicado: (2022)

ALK Inhibitors in the Treatment of ALK Positive NSCLC
por: Khan, Muhammad, et al.
Publicado: (2019)

The use of real-world evidence in ICER’s scoping process and clinical evidence assessments
por: Jiao, Boshen, et al.
Publicado: (2020)

Understanding the Economic Value of Molecular Diagnostic Tests: Case Studies and Lessons Learned
por: Towse, Adrian, et al.
Publicado: (2013)

Alternative Treatment Options to ALK Inhibitor Monotherapy for EML4-ALK-Driven Lung Cancer
por: Papageorgiou, Savvas, et al.
Publicado: (2022)

Anti-ALK Antibodies in Patients with ALK-Positive Malignancies Not Expressing NPM-ALK
por: Damm-Welk, Christine, et al.
Publicado: (2016)

Ants prefer the option they are trained to first
por: Oberhauser, Felix B., et al.
Publicado: (2022)

Use of real-world evidence in economic assessments of pharmaceuticals in the United States
por: Lee, Woojung, et al.
Publicado: (2021)

A human ex vivo coculture model to investigate peritoneal metastasis and innovative treatment options
por: Mönch, Dina, et al.
Publicado: (2021)

Ex ante and ex post effects of hybrid index insurance in Bangladesh()
por: Hill, Ruth Vargas, et al.
Publicado: (2019)

Ex ante assessment of sustainable marketing investments
por: Vollero, Agostino, et al.
Publicado: (2022)

Personalized treatment options for ALK-positive metastatic non-small-cell lung cancer: potential role for Ceritinib
por: El-Osta, Hazem, et al.
Publicado: (2015)

Podcast on Lorlatinib as a First-Line Treatment Option for Patients with ALK-Positive Metastatic NSCLC with Brain Metastasis
por: Liu, Geoffrey, et al.
Publicado: (2023)

Pooled safety analyses of ALK-TKI inhibitor in ALK-positive NSCLC
por: Zhu, Qian, et al.
Publicado: (2017)

Unequal chances: ex ante fairness and individual control
por: Micheli, Leticia, et al.
Publicado: (2020)

Value of CT features for predicting EGFR mutations and ALK positivity in patients with lung adenocarcinoma
por: Han, Xiaoyu, et al.
Publicado: (2021)

Peptides derived from the dependence receptor ALK are proapoptotic for ALK-positive tumors
por: Aubry, A, et al.
Publicado: (2015)

Positive and negative incentive contrasts lead to relative value perception in ants
por: Wendt, Stephanie, et al.
Publicado: (2019)

Effect of the land area elevation on the collective choice in ants
por: Bles, Olivier, et al.
Publicado: (2017)

ALK Inhibitor Treatment Patterns and Outcomes in Real-World Patients with ALK-Positive Non-Small-Cell Lung Cancer: A Retrospective Cohort Study
por: Wang, Michelle, et al.
Publicado: (2023)

Lorlatinib Effectiveness and Quality-of-Life in Patients with ALK-Positive NSCLC Who Had Failed Second-Generation ALK Inhibitors: Canadian Real-World Experience
por: Rupp, Martin, et al.
Publicado: (2023)

Sequential therapy with crizotinib and a second-generation ALK inhibitor versus direct therapy of a second-generation ALK inhibitor in ALK-positive advanced lung cancer: a real-world study
por: Wei, Jingwen, et al.
Publicado: (2023)

Rationale for co-targeting IGF-1R and ALK in ALK fusion positive lung cancer
por: Lovly, Christine M., et al.
Publicado: (2014)

Immunoassays for the quantification of ALK and phosphorylated ALK support the evaluation of on‐target ALK inhibitors in neuroblastoma
por: Tucker, Elizabeth R., et al.
Publicado: (2017)

Mechanisms of Acquired Resistance to ALK Inhibitors and the Rationale for Treating ALK-positive Lung Cancer
por: Isozaki, Hideko, et al.
Publicado: (2015)

ALK is a critical regulator of the MYC-signaling axis in ALK positive lung cancer
por: Pilling, Amanda B., et al.
Publicado: (2018)

Immune Response against ALK in Children with ALK-Positive Anaplastic Large Cell Lymphoma
por: Stadler, Serena, et al.
Publicado: (2018)

Synergistic activity of ALK and mTOR inhibitors for the treatment of NPM-ALK positive lymphoma
por: Redaelli, Sara, et al.
Publicado: (2016)

Holistic View of ALK TKI Resistance in ALK-Positive Anaplastic Large Cell Lymphoma
por: Wang, Yuan, et al.
Publicado: (2022)

Inhibiting ALK-TOPK signaling pathway promotes cell apoptosis of ALK-positive NSCLC
por: Xiao, Juanjuan, et al.
Publicado: (2022)

Interactive and synergistic relationships among different types of innovations()
por: Whang, Jeong-Bin, et al.
Publicado: (2023)

Systematic review of sequencing of ALK inhibitors in ALK-positive non-small-cell lung cancer
por: Barrows, Stephanie M, et al.
Publicado: (2019)

ALK variants, PD-L1 expression, and their association with outcomes in ALK-positive NSCLC patients
por: Chang, Gee-Chen, et al.
Publicado: (2020)

Integrated analysis of the clinical consequence and associated gene expression of ALK in ALK-positive human cancers
por: Saifullah, et al.
Publicado: (2022)

The Evolutionary Innovation of Nutritional Symbioses in Leaf-Cutter Ants
por: Aylward, Frank O., et al.
Publicado: (2012)

Cytologic Features of ALK-Positive Pulmonary Adenocarcinoma
por: Ha, Seung Yeon, et al.
Publicado: (2013)

New options in the management of intractable ALK(+) metastatic non-small-cell lung cancer
por: Weise, Amy M, et al.
Publicado: (2014)

Show no quarter: combating plausible lies with ex-ante honesty oaths
por: Babin, J. Jobu, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_msruu0fjmc0mnr8bb6qdqrq3gb